OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
Article meta
Article Date = 25 February 2026
Article URL = https://www.nature.com/articles/s41586-026-10149-8
Article Title = OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
Article Image = https://www.nature.com/articles/s41586-026-10149-8
Summary
This Nature study used in vivo gain-of-function CRISPRa screening and follow-up ORF validation to identify GPCR OR7A10 as a potent “booster” of CAR‑NK anti-tumour activity. Engineering primary human CAR‑NK cells to overexpress OR7A10 enhanced cytotoxicity, cytokine production, activation markers and persistence across multiple donors and NK sources (peripheral blood and cord blood). OR7A10 effects synergised with diverse CAR constructs and NK activating receptors (for example NKp46) and improved control of solid tumour xenografts in mice.
The authors characterised signalling downstream of OR7A10 (involving GNAS/cAMP/PKA, ERK and NF‑kB pathways), used inhibitors and gene knockouts to map mechanisms, and performed bulk and single‑cell transcriptomics to define enriched activation and proliferation programmes. Safety analyses included whole‑genome sequencing, cytokine assays and histology; no gross genomic rearrangements or overt toxicity were reported. Data and code are available on GitHub and GEO (GSE309802), and a patent application related to the work has been filed.
Key Points
- In vivo CRISPRa and ORF mini‑screens identified OR7A10 as a top enhancer of CAR‑NK anti‑tumour function.
- OR7A10 overexpression in primary CAR‑NK cells increases killing, cytokine release, activation markers (CD69, CD25, 4‑1BB) and reduces exhaustion markers after repeated challenge.
- Effects are reproducible across donors and NK sources (peripheral blood and cord blood) and boost multiple CAR platforms (HER2, B7H3, CD22, etc.).
- OR7A10 signalling engages canonical GPCR pathways (GNAS → cAMP/PKA; ERK and NF‑kB) — genetic or pharmacologic perturbation of these nodes modulates the booster effect.
- Single‑cell transcriptomics show OR7A10 drives programmes of leukocyte activation, proliferation and effector function across NK subsets.
- Combined constructs (CAR + IL‑15 + OR7A10) further enhanced persistence and tumour control in xenograft models without clear signs of systemic toxicity in reported assays.
- Data and code are openly available (GitHub repo and GEO accession GSE309802), supporting reproducibility and follow‑on studies.
- Yale and Cellinfinity Bio have filed a patent related to these findings; lead authors disclose relevant company affiliations.
Context and relevance
The study addresses a major limitation for cell therapy in solid tumours: NK cells and CAR‑NK approaches often struggle with persistence, trafficking and exhaustion in the tumour microenvironment. By showing a GPCR (OR7A10) can be engineered to broadly amplify NK effector programmes and synergise with CAR signalling and IL‑15, the work suggests a new, modular engineering axis for next‑generation adoptive NK therapies. This fits into an active field of NK optimisation (checkpoint edits, cytokine support, homing receptors) and provides a biologically plausible target with mechanistic data and cross‑platform validation.
Why should I read this?
Short and blunt: if you care about making NK cell therapy actually work in solid tumours, this paper’s worth five minutes. It shows a tweak — overexpressing a GPCR, OR7A10 — that reliably boosts killing, persistence and activation across donors and CAR designs, with mechanistic depth and available data/code. Handy if you’re designing CAR‑NK constructs, thinking about combinatorial engineering (CAR + cytokine + GPCR), or tracking translational advances in cell therapy.
Author style
Punchy: this is a practical, well‑validated engineering advance that could materially change how researchers design CAR‑NK products. The combination of unbiased in vivo screens, donor‑validated primary cell work, single‑cell profiling and safety checks makes the findings immediately relevant — not just another cell‑culture curiosity. If you work in translational immunotherapy, it’s a must‑skim and probably a must‑read.